TABLE 1.
Frequency of occurrence of lefamulin MICs for all pathogens tested
| Organism (no. of isolates) | Cumulative % of isolates inhibited at lefamulin MIC (μg/ml) of: |
MIC50 (μg/ml) | MIC90 (μg/ml) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤0.008 | 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | >8 | |||
| S. pneumoniae (3,923) | 0.1 | 1.8 | 11.4 | 55.1 | 93.7 | 99.6 | 99.9 | 100.0 | 0.06 | 0.12 | ||||
| Penicillin nonsusceptible, nonmeningitis (≥4 μg/ml) (189) | 0.0 | 1.1 | 7.9 | 64.0 | 98.4 | 100.0 | 0.06 | 0.12 | ||||||
| Ceftriaxone nonsusceptible (≥2 μg/ml) (155) | 0.0 | 0.6 | 10.3 | 63.9 | 99.4 | 100.0 | 0.06 | 0.12 | ||||||
| Erythromycin nonsusceptible(≥0.5 μg/ml) (1,348) | 0.2 | 2.2 | 12.4 | 52.9 | 93.1 | 99.0 | 99.7 | 100.0 | 0.06 | 0.12 | ||||
| Levofloxacin nonsusceptible (≥4 μg/ml) (47) | 0.0 | 8.5 | 23.4 | 68.1 | 89.4 | 97.9 | 97.9 | 100.0 | 0.06 | 0.25 | ||||
| MDRa (821) | 0.4 | 2.9 | 15.8 | 61.1 | 96.3 | 99.8 | 99.8 | 100.0 | 0.06 | 0.12 | ||||
| XDRa (181) | 0.0 | 0.6 | 7.2 | 64.6 | 98.9 | 100.0 | 0.06 | 0.12 | ||||||
| S. aureus (2,919) | 26.0 | 88.9 | 99.2 | 99.6 | 99.7 | 99.8 | 99.8 | 99.8 | 99.8 | 100.0 | 0.06 | 0.12 | ||
| Methicillin susceptible (1,981) | 25.6 | 95.2 | 99.7 | 99.7 | 99.8 | 99.9 | >99.9 | >99.9 | >99.9 | 100.0 | 0.06 | 0.06 | ||
| Methicillin resistant (938) | 26.9 | 75.7 | 98.2 | 99.4 | 99.5 | 99.6 | 99.7 | 99.8 | 99.8 | 100.0 | 0.06 | 0.12 | ||
| H. influenzae (1,086) | 1.7 | 20.4 | 69.4 | 93.8 | 99.1 | 99.9 | 100.0 | 0.5 | 1 | |||||
| β-lactamase negative (835) | 1.9 | 20.0 | 67.5 | 93.2 | 98.9 | 100.0 | 0.5 | 1 | ||||||
| β-lactamase positive (251) | 1.2 | 21.9 | 75.7 | 96.0 | 99.6 | 99.6 | 100.0 | 0.5 | 1 | |||||
| M. catarrhalis (667) | 1.0 | 2.4 | 11.1 | 88.3 | 99.9 | 100.0 | 0.06 | 0.12 | ||||||
a
MDR and XDR status was based on nonsusceptibility to ≥3 and ≥5 classes, respectively, of the following antimicrobial agents, as described by Golden et al. (30) and applying the following breakpoints: penicillin (MIC, ≥4 μg/ml), ceftriaxone (MIC, ≥2 μg/ml), erythromycin (MIC, ≥0.5 μg/ml), clindamycin (MIC, ≥0.5 μg/ml), levofloxacin (MIC, ≥4 μg/ml), tetracycline (MIC, ≥2 μg/ml), and trimethoprim-sulfamethoxazole (MIC, ≥1 μg/ml). MDR, multidrug resistant; XDR, extensive drug resistant.